Solvent Polarity-Directed Morphological Transformation of Zinc Porphyrin Assemblies for Enhanced Photodynamic Therapy of Glioblastoma.

Authors

Jichao Chen, Manzhen Wang, Xingmei He, Qinqin Ma, Qingxiang Zhu, Yisheng Liu, Guan Huang, Chenbo Wang, Jiajie Sun, Yong Zhong

Published in

ACS applied materials & interfaces. Aug 31, 2026. Epub Aug 31, 2026.

Abstract

Glioblastoma is one of the most aggressive brain cancers with poor prognosis. Photodynamic therapy (PDT) is an efficient and noninvasive strategy for glioblastoma treatment. Porphyrins represent common photosensitizers for PDT but suffer from poor water solubility and low reactive oxygen species (ROS) yield. Herein, we report a porphyrin photosensitizer with enhanced ROS via a cascade fabrication involving the self-assembly of zinc meso-tetra(4-pyridyl)porphyrin (ZnTPyP) into tetragonal nanorods (NRs), followed by a polarity-driven morphological transition into hexagonal nanowires (NWs). Spectroscopic monitoring revealed a continuous disassembly-reassembly mechanism for this morphological transition, with a critical transition observed at 40% (v/v) ethanol. Different from the monoaxial Zn-N coordination and symmetric π-stacked structure of tetragonal NRs, the hexagonal NWs adopt a dual axial coordination and J-aggregated conjugated packing to form open hexagonal channels. This structural reorganization of NWs was accompanied by a significant absorption redshift, enhanced light harvesting, and a 1.9-fold increase in ROS generation. Upon 635 nm irradiation, the NWs exhibited a superior photodynamic effect (79.9%) compared to that of tetragonal NRs (44.5%). Apolipoprotein E (ApoE)-modified NWs traversed the blood-brain barrier and efficiently inhibited glioma growth in an orthotopic glioma model via enhanced PDT. Collectively, the solvent polarity modulation offers a powerful and general strategy to engineer supramolecular assembly architectures, paving the way for advanced photoactive nanotheranostics against brain diseases.

PMID:
42687231
Bibliographic data and abstract were imported from PubMed on 03 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.